Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/29397
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | RIDKER, Paul M. | - |
dc.contributor.author | ROSE, Lynda M. | - |
dc.contributor.author | KASTELEIN, John J. P. | - |
dc.contributor.author | SANTOS, Raul D. | - |
dc.contributor.author | WEI, Caimiao | - |
dc.contributor.author | REVKIN, James | - |
dc.contributor.author | YUNIS, Carla | - |
dc.contributor.author | TARDIF, Jean-Claude | - |
dc.contributor.author | SHEAR, Charles L. | - |
dc.date.accessioned | 2018-11-21T17:00:34Z | - |
dc.date.available | 2018-11-21T17:00:34Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | JOURNAL OF CLINICAL LIPIDOLOGY, v.12, n.4, p.958-965, 2018 | - |
dc.identifier.issn | 1933-2874 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/29397 | - |
dc.description.abstract | BACKGROUND: Familial hypercholesterolemia (FH) is a dominant genetic disorder associated with elevated low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic events. Although therapeutic monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) are indicated for LDL-C reduction among adult patients with FH, placebo-controlled outcome data among FH patients are scant. OBJECTIVE: Directly compare the efficacy of PCSK9 inhibition as compared to placebo on hard cardiovascular outcomes in FH patients enrolled in the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) program. METHODS: We estimated the efficacy of PCSK9 inhibition with bococizumab on future cardiovascular event rates among 1578 FH patients and 15,959 patients without FH who were selected for comparable lipid levels (on-statin levels of LDL-C > 100 mg/dL or non high-density lipoprotein cholesterol > 130 mg/dL). All patients were randomized by computer generated codes to bococizumab 150 mg subcutaneously every 2 weeks or to matching placebo in the SPIRE clinical trials program and were followed over a median period of 11.2 months for major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death). Analysis is by intention to treat. The SPIRE trials are closed and registered at ClinicalTrials.gov: NCT01968954, NCT01968967, NCT02100514, NCT01968980, NCT01975376, and NCT01975389. RESULTS: Compared to non-FH patients, FH patients enrolled in the SPIRE trials were on average younger (58 vs 63 years), more likely to be women (42 vs 35%), more likely to be primary prevention patients (42 vs 23%), had higher mean baseline LDL-C levels (151 vs 127 mg/dL), and lower rates of diabetes (25 vs 52%) and hypertension (59 vs 82%). FH and non-FH patients both had 55% reductions in LDL-C with bococizumab. Among FH patients, major adverse cardiovascular events occurred among 18 of 781 allocated to bococizumab and 22 of 797 allocated to placebo (hazard ratio 0.83; 95% confidence interval 0.44-1.54, P=.55). This best estimate of effect was similar in magnitude to that observed in the much larger group of patients without FH (hazard ratio 0.79, 95% confidence interval 0.64-0.97, P=.023) with no statistically significant evidence of heterogeneity between groups (P=.87). Incidence rate ratios comparing bococizumab to placebo for adverse events were similar among those with and without FH. The proportion of patients developing antidrug antibodies was higher among those with FH compared to those without FH (43% vs 36%, P<.001). CONCLUSIONS: In these randomized placebo-controlled data, the subgroup of statin-treated FH patients had a similar magnitude of risk reduction for hard cardiovascular events with the PCSK9 inhibitor bococizumab as did patients without FH, with no evidence of statistical heterogeneity between groups. | - |
dc.description.sponsorship | Pfizer, New York, NY | - |
dc.language.iso | eng | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.ispartof | Journal of Clinical Lipidology | - |
dc.rights | restrictedAccess | - |
dc.subject | Familial hypercholesterolemia | - |
dc.subject | PCSK9 inhibition | - |
dc.subject | Event reduction | - |
dc.subject.other | density-lipoprotein cholesterol | - |
dc.subject.other | placebo-controlled trial | - |
dc.subject.other | 9 monoclonal-antibody | - |
dc.subject.other | amg 145 | - |
dc.subject.other | double-blind | - |
dc.subject.other | risk | - |
dc.subject.other | evolocumab | - |
dc.subject.other | disease | - |
dc.subject.other | association | - |
dc.subject.other | prevalence | - |
dc.title | Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab | - |
dc.type | article | - |
dc.rights.holder | Copyright ELSEVIER SCIENCE INC | - |
dc.contributor.groupauthor | Studies PCSK9 Inhibition | - |
dc.contributor.groupauthor | Reduction Vasc Events SPIRE Invest | - |
dc.identifier.doi | 10.1016/j.jacl.2018.03.088 | - |
dc.identifier.pmid | 29685591 | |
dc.subject.wos | Pharmacology & Pharmacy | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | RIDKER, Paul M.:Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA | - |
hcfmusp.author.external | ROSE, Lynda M.:Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA | - |
hcfmusp.author.external | KASTELEIN, John J. P.:Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands | - |
hcfmusp.author.external | WEI, Caimiao:Pfizer Inc, New York, NY USA | - |
hcfmusp.author.external | REVKIN, James:Pfizer Inc, New York, NY USA | - |
hcfmusp.author.external | YUNIS, Carla:Pfizer Inc, New York, NY USA | - |
hcfmusp.author.external | TARDIF, Jean-Claude:Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada | - |
hcfmusp.author.external | SHEAR, Charles L.:CiVi Biopharma, Philadelphia, PA USA | - |
hcfmusp.description.beginpage | 958 | - |
hcfmusp.description.endpage | 965 | - |
hcfmusp.description.issue | 4 | - |
hcfmusp.description.volume | 12 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000442192700018 | - |
hcfmusp.origem.id | 2-s2.0-85045896981 | - |
hcfmusp.publisher.city | NEW YORK | - |
hcfmusp.publisher.country | USA | - |
hcfmusp.relation.reference | Besseling J, 2016, J AM COLL CARDIOL, V68, P252, DOI 10.1016/j.jacc.2016.04.054 | - |
hcfmusp.relation.reference | Besseling J, 2014, ATHEROSCLEROSIS, V233, P219, DOI 10.1016/j.atherosclerosis.2013.12.020 | - |
hcfmusp.relation.reference | Collins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5 | - |
hcfmusp.relation.reference | de Ferranti SD, 2016, CIRCULATION, V133, P1067, DOI 10.1161/CIRCULATIONAHA.115.018791 | - |
hcfmusp.relation.reference | Gidding SS, 2015, CIRCULATION, V132, P2167, DOI 10.1161/CIR.0000000000000297 | - |
hcfmusp.relation.reference | Huijgen R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009220 | - |
hcfmusp.relation.reference | Kastelein JJP, 2017, J CLIN LIPIDOL, V11, P195, DOI 10.1016/j.jacl.2016.12.004 | - |
hcfmusp.relation.reference | Kastelein JJP, 2015, EUR HEART J, V36, P2996, DOI 10.1093/eurheartj/ehv370 | - |
hcfmusp.relation.reference | Khera AV, 2016, J AM COLL CARDIOL, V67, P2578, DOI 10.1016/j.jacc.2016.03.520 | - |
hcfmusp.relation.reference | Lotta LA, 2016, JAMA-J AM MED ASSOC, V316, P1383, DOI 10.1001/jama.2016.14568 | - |
hcfmusp.relation.reference | Nolting PRWD, 2003, J INTERN MED, V253, P161 | - |
hcfmusp.relation.reference | Nordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273 | - |
hcfmusp.relation.reference | Raal F, 2012, CIRCULATION, V126, P2408, DOI 10.1161/CIRCULATIONAHA.112.144055 | - |
hcfmusp.relation.reference | Raal FJ, 2017, LANCET DIABETES ENDO, V5, P280, DOI 10.1016/S2213-8587(17)30044-X | - |
hcfmusp.relation.reference | Raal FJ, 2015, LANCET, V385, P331, DOI 10.1016/S0140-6736(14)61399-4 | - |
hcfmusp.relation.reference | Raal FJ, 2015, LANCET, V385, P341, DOI 10.1016/S0140-6736(14)61374-X | - |
hcfmusp.relation.reference | Ridker PM, 2017, NEW ENGL J MED, V376, P1527, DOI 10.1056/NEJMoa1701488 | - |
hcfmusp.relation.reference | Ridker PM, 2017, ANN INTERN MED, V166, P901, DOI 10.7326/M17-0855 | - |
hcfmusp.relation.reference | Ridker PM, 2017, NEW ENGL J MED, V376, P1517, DOI 10.1056/NEJMoa1614062 | - |
hcfmusp.relation.reference | Ridker PM, 2014, LANCET, V384, P607, DOI 10.1016/S0140-6736(14)61009-6 | - |
hcfmusp.relation.reference | Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI 10.1056/NEJMoa1615664 | - |
hcfmusp.relation.reference | Seidah NG, 2012, NAT REV DRUG DISCOV, V11, P367, DOI 10.1038/nrd3699 | - |
hcfmusp.relation.reference | Stein EA, 2013, CIRCULATION, V128, P2113, DOI 10.1161/CIRCULATIONAHA.113.004678 | - |
hcfmusp.relation.reference | Stein EA, 2012, LANCET, V380, P29, DOI 10.1016/S0140-6736(12)60771-5 | - |
hcfmusp.relation.reference | Vallejo-Vaz AJ, 2017, CIRCULATION, V136, P1878, DOI 10.1161/CIRCULATIONAHA.117.027966 | - |
dc.description.index | MEDLINE | - |
dc.identifier.eissn | 1876-4789 | - |
hcfmusp.citation.scopus | 41 | - |
hcfmusp.scopus.lastupdate | 2024-03-07 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCP Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_RIDKER_Cardiovascular_event_reduction_with_PCSK9_inhibition_among_1578_2018.PDF Restricted Access | publishedVersion (English) | 250.83 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.